Slide 1: Clinical Stage Antiviral Drug Development Company
BIOTRON LIMITED (ASX:BIT) Clinical Stage An;viral Drug Development Company Michelle Miller CEO & Managing Director +61 (0) 412 313 329 mmiller@biotron.com.au
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited and certain of the plans and objectives of its management. These statements are statements that are not histor
Slide 3: Biotron Limited Overview
Biotron Limited Overview • Clinical stage an-viral drug development company • Clinical programs for Hepa--s C virus (HCV) and HIV • Earlier stage programs include Dengue and others • Spun out from Australian Na-onal University, Canberra, Australia • Headquartered in Sydney, Australia • IPO Jan 2001
Slide 4: Biotron - Advanced Pipeline of Clinical Programs
Biotron -‐ Advanced Pipeline of Clinical Programs VIRAL INDICATION DISCOVERY PRECLINICAL PHASE 1a PHASE 1b PHASE 2a PHASE 2b STATUS TARGET • Ph 2a complete; Hep C p7 • Ph 2b (3 mth dosing) scheduled for 4Q13 HIV Vpu • Ph 2a complete • Ph 2 completed HIV/Hep C Vpu/p7 clinical phase Next • Ready for
Slide 5: BIT225 – New Class of HCV DAA Drug
BIT225 – New Class of HCV DAA Drug ü Novel, oral, small molecule compound ü Only one of its class (p7 inhibitor) in clinical trials ü Inhibits viral assembly; ac-ve at later stage of virus life cycle to polymerase and protease inhibitors ü Doesn’t readily generate resistance ü Clinically ac-ve
Slide 6: BIT225 – Proven Clinical Activity Against HCV
BIT225 – Proven Clinical Ac;vity Against HCV BIT225 Interferon + Ribavirin BIT225-‐005 Placebo 0 4 wks 12 wks 48 wks 12 WEEKS 48 WEEKS Treatment Early Virological Response* Sustained Virological Response* 400 mg BIT225 + IFN/RBV 86% 100% 200 mg BIT225 + IFN/RBV 88% 88% Placebo + IFN/RBV 63% 75% *vi
Slide 7: BIT225 – HIV / HCV Co-Infected Trial
BIT225 – HIV / HCV Co-‐Infected Trial BIT225-‐006 BIT225 Interferon + Ribavirin ART 0 1 wks 5 wks 48 wks • Phase 2 HIV/HCV trial -‐ completed clinical phase in July 2013 – ~30% of HIV-‐infected people in the USA are also HCV-‐infected – Significantly worse prognosis than mono-‐infected pa-ents
Slide 8: Proven Clinical Activity Against HIV
BIT225 – Proven Clinical Ac;vity Against HIV • Phase 1b/2a randomised, placebo controlled, double-‐blind trial 16 Placebo BIT225 HIV-‐1 Replica-on (pg/200uL) 14 – 24 pa-ents, HIV-‐1 posi-ve, treatment-‐naïve 12 – 10 days dosing with BIT225 (monotherapy) 10 8 • Results demonstrated that: 6 1. BIT
Slide 9: BIT225 – Multiple Market Opportunities
BIT225 –Mul;ple Market Opportuni;es • Hepa;;s C • Poten-al for future combina-on cocktails with polymerase and protease inhibitors • Unique mode of ac-on • Good drug-‐drug interac-on profile • Limited alterna-ve classes for combina-ons (preven-on of resistance) • Poten-al to fill gaps led by other DA
Slide 10: Key Financials and Facts
Key Financials and Facts BIOTRON ASX Code LIMITED KEY FINANCIALS price BIT history chart Mr Michael Hoy BOARD AND MANAGEMENT Chairman Recent Share Price (24 Oct 2013) A$0.10 Dr Michelle Miller CEO & Managing Director 52 Week High A$0.15 Dr Denis Wade Non-‐Execu;ve Director 52 Week Low A$0.08 Dr Sus